Host: Christina Y. Weng, MD, MBA Host: Durga Borkar, MD, MMCi The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME),

Host: Jayanth Sridhar, MD Host: Sabin Dang, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do the

Host: Jayanth Sridhar, MD Host: Sabin Dang, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do the

Host: Sabin Dang, MD Host: Jayanth Sridhar, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do the

Host: Christina Y. Weng, MD, MBA Host: Durga Borkar, MD, MMCi The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME),

Host: Durga Borkar, MD, MMCi Host: Christina Y. Weng, MD, MBA The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME),

Guest: Mazen Hanna, MD Guest: Marianna Fontana, MD Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. Mazen Hanna and Mari

Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA Guest: Antoni Bays-Gens, MD, PhD, FESC, FHFA Guest: Ovidiu Chioncel, MD, PhD Guest: Marco Metra, MD Experts agree intravenous iron treatment for iron-deficient patients with heart fai

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Charles P. Vega, MD We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborativ

Host: Joseph Mikhael, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians ability to distinguish between relapse and progression of disea